Metabolic Targets in Nonalcoholic Fatty Liver Disease

por Esler, William P., Bence, Kendra K.
Publicado 2019

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study

por Bergman, Arthur, Carvajal‐Gonzalez, Santos, Tarabar, Sanela, Saxena, Aditi R., Esler, William P., Amin, Neeta B.
Publicado 2020

Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) Reduces Proliferation and De Novo Lipogenesis of EGFRvIII Human Glioblastoma Cells

por Jones, Jessica E. C., Esler, William P., Patel, Rushi, Lanba, Adhiraj, Vera, Nicholas B., Pfefferkorn, Jeffrey A., Vernochet, Cecile
Publicado 2017

Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems

por Ross, Trenton T., Crowley, Collin, Kelly, Kenneth L., Rinaldi, Anthony, Beebe, David A., Lech, Matthew P., Martinez, Robert V., Carvajal-Gonzalez, Santos, Boucher, Magalie, Hirenallur-Shanthappa, Dinesh, Morin, Jeffrey, Opsahl, Alan C., Vargas, Sarah R., Bence, Kendra K., Pfefferkorn, Jeffrey A., Esler, William P.
Publicado 2020

Targeting host metabolism by inhibition of acetyl-Coenzyme A carboxylase reduces flavivirus infection in mouse models

por Jiménez de Oya, Nereida, Esler, William P., Huard, Kim, El-Kattan, Ayman F., Karamanlidis, Georgios, Blázquez, Ana-Belén, Ramos-Ibeas, Priscila, Escribano-Romero, Estela, Louloudes-Lázaro, Andrés, Casas, Josefina, Sobrino, Francisco, Hoehn, Kyle, James, David E., Gutiérrez-Adán, Alfonso, Saiz, Juan-Carlos, Martín-Acebes, Miguel A.
Publicado 2019

Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes

por Griffith, David A., Kung, Daniel W., Esler, William P., Amor, Paul A., Bagley, Scott W., Beysen, Carine, Carvajal-Gonzalez, Santos, Doran, Shawn D., Limberakis, Chris, Mathiowetz, Alan M., McPherson, Kirk, Price, David A., Ravussin, Eric, Sonnenberg, Gabriele E., Southers, James A., Sweet, Laurel J., Turner, Scott M., Vajdos, Felix F.
Publicado 2014

Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946)

por Scott, William J., Hentemann, Martin F., Rowley, R. Bruce, Bull, Cathy O., Jenkins, Susan, Bullion, Ann M., Johnson, Jeffrey, Redman, Anikó, Robbins, Arthur H., Esler, William, Fracasso, R. Paul, Garrison, Timothy, Hamilton, Mark, Michels, Martin, Wood, Jill E., Wilkie, Dean P., Xiao, Hong, Levy, Joan, Stasik, Enrico, Liu, Ningshu, Schaefer, Martina, Brands, Michael, Lefranc, Julien
Publicado 2016

Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction

por Gutierrez, Jemy A., Liu, Wei, Perez, Sylvie, Xing, Gang, Sonnenberg, Gabriele, Kou, Kou, Blatnik, Matt, Allen, Richard, Weng, Yan, Vera, Nicholas B., Chidsey, Kristin, Bergman, Arthur, Somayaji, Veena, Crowley, Collin, Clasquin, Michelle F., Nigam, Anu, Fulham, Melissa A., Erion, Derek M., Ross, Trenton T., Esler, William P., Magee, Thomas V., Pfefferkorn, Jeffrey A., Bence, Kendra K., Birnbaum, Morris J., Tesz, Gregory J.
Publicado 2021